Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Nature|March 4, 2026
A glucocorticoid-FAS axis controls immune evasion during metastatic seedingMonica Cassandras, Xavier Sanchez, Lauren Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerSteven J Isakoff, Erica L Mayer, Lei He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Geriatric Oncology|September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancerRachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Journal of the National Cancer Institute|October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Nature Genetics|April 27, 2023
Single duplex DNA sequencing with CODEC detects mutations with high sensitivityJin H Bae, Ruolin Liu, Eugenia Roberts, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast CancerErica L Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of the National Cancer Institute|April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapyChristina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Nature|March 4, 2026
A glucocorticoid-FAS axis controls immune evasion during metastatic seedingMonica Cassandras, Xavier Sanchez, Lauren Hsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerSteven J Isakoff, Erica L Mayer, Lei He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Geriatric Oncology|September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancerRachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Journal of the National Cancer Institute|October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Nature Genetics|April 27, 2023
Single duplex DNA sequencing with CODEC detects mutations with high sensitivityJin H Bae, Ruolin Liu, Eugenia Roberts, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast CancerErica L Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of the National Cancer Institute|April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapyChristina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Pageof 12